Cargando…
Off-Label Use of Bumetanide for Brain Disorders: An Overview
Bumetanide (BTN or BUM) is a FDA-approved potent loop diuretic (LD) that acts by antagonizing sodium-potassium-chloride (Na-K-Cl) cotransporters, NKCC1 (SLc12a2) and NKCC2. While NKCC1 is expressed both in the CNS and in systemic organs, NKCC2 is kidney-specific. The off-label use of BTN to modulate...
Autores principales: | Kharod, Shivani C., Kang, Seok Kyu, Kadam, Shilpa D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491514/ https://www.ncbi.nlm.nih.gov/pubmed/31068771 http://dx.doi.org/10.3389/fnins.2019.00310 |
Ejemplares similares
-
Bumetanide Prevents Brain Trauma-Induced Depressive-Like Behavior
por: Goubert, Emmanuelle, et al.
Publicado: (2019) -
Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures
por: Ben-Ari, Yehezkel, et al.
Publicado: (2016) -
Bumetanide Effects on Resting-State EEG in Tuberous Sclerosis Complex in Relation to Clinical Outcome: An Open-Label Study
por: Juarez-Martinez, Erika L., et al.
Publicado: (2022) -
Comparison of Brain Maturation among Species: An Example in Translational Research Suggesting the Possible Use of Bumetanide in Newborn
por: Pressler, Ronit, et al.
Publicado: (2013) -
Bumetanide for autism: Open‐label trial in six children
por: Fernell, Elisabeth, et al.
Publicado: (2021)